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Abstract
Lovastatin, an inhibitor of protein prenylation, was reported to inhibit DNA synthesis and induce apoptosis in cultured
 .cells. This report describes the morphological consequences of lovastatin treatment. Lovastatin 50 mM induced mesangial
cell rounding and disassembly of actin stress fibers within 24 to 48 h. After 48 to 72 h of lovastatin treatment, the cells
detached from the substratum and underwent apoptotic cell death as evidenced by condensed nuclear chromatin, nuclear
fragmentation, cell blebbing and decrease in cell size. Time lapse cinematography revealed that lovastatin caused cell
rounding by either inhibiting cytokinesis or cell spreading following cytokinesis. Lovastatin-induced cell rounding,
detachment, and apoptosis were dependent upon cell proliferation. These effects were prevented by serum deprivation to
inhibit cell proliferation or by plating cells at densities which resulted in contact inhibition of cell growth. Lovastatin-in-
duced mesangial cell rounding and apoptosis were also prevented by the inclusion of the isoprenoids all-trans-farnesol or
all-trans-geranylgeraniol in the incubation medium. These results indicate that the effects of lovastatin were mediated by
inhibition of protein isoprenylation because exogenous all-trans-geranylgeraniol can be used only in protein prenylation.
The small GTP-binding protein RhoA, which may be important for cell spreading and cytokinesis, accumulated in the
cytosol following treatment with lovastatin, suggestive of its inactivation. This effect was also prevented by the inclusion of
either farnesol or geranylgeraniol in the incubation medium. Thus, lovastatin-induced apoptosis in mesangial cells occurs by
interfering with prenylation dependent mitotic and post-mitotic events. q 1997 Elsevier Science B.V.
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1. Introduction
Cells grown in lovastatin, a potent inhibitor of
3-hydroxy-3-methylglutaryl-coenzyme A HMG–
.CoA reductase, develop a round, refractile morphol-
w x w xogy 1 , show inhibition of cell growth 2 and un-
w xdergo apoptosis 3 . Such cells display loss of actin
) Corresponding author. Fax: q1-210-5672367; E-mail: kreis-
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stress fibers without apparent changes in the micro-
w xtubular lattice or intermediate filament structure 1 .
The main function of lovastatin is to prevent the
w xreduction of HMG–CoA to mevalonate 4 . Meval-
 .onate is converted into 5-carbon units C5 , called
 . w xisopentenyl pyrophosphate IPP 5 . Two C5 units
combine to form a C10 compound, geranyl pyrophos-
phate, which then combines with IPP to form farnesol
 .pyrophosphate FPP , a C15 compound. FPP is the
common intermediate for the biosynthesis of choles-
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terol, dolichol and ubiquinone as well as protein
w xisoprenylation 5 . In addition, FPP combines with
 .another C5 unit IPP to form a C20 compound,
 .all-trans-geranylgeranyl pyrophosphate GGPP .
These conversions are prevented in the presence of
lovastatin due to the absence of the IPP units. Un-
bound all-trans-GGPP appears to be uniquely des-
tined for the posttranslational modification of differ-
w xent groups of proteins 5 . The isoprenoids FPP and
GGPP are transferred by farnesyl and geranylgeranyl
protein transferases respectively to various proteins,
such as small GTP-binding proteins, for targeting and
activation.
Small GTP-binding proteins of the Ras superfam-
ily, including Rho, Rab, Raf, Rac, Rap, etc. are
involved in such diverse cellular functions as cytoki-
w x w x w xnesis 6 , cell motility 7 , cell adhesion 8 and cell
w xproliferation 9 . All members of this family, except
Rab, have a C AAX sequence at their C-terminal,
where A is any aliphatic amino acid and X is a
COOH-terminal amino acid that specifies which
prenyltransferase will act. Although recent experi-
w xments suggest more complex relationships 10 , it is
generally believed that C AAX farnesyltransferase
preferentially recognizes methionine or serine at the
X position and C AAX geranylgeranyl transferase
w xprefers leucine at the X position 11 . During post-
translational modification, an isoprenyl group for
.example, farnesyl or geranylgeranyl is first attached
to the cysteine group, then the AAX sequence is
cleaved and the isoprenylated cysteine is carboxy-
w xmethylated 12 . The Ras proteins are farnesylated
while most other small GTP-binding proteins are
w xgeranylgeranylated 13 . RhoB is both geranylgerany-
w xlated as well as farnesylated 10 .
Once prenylated, the small GTP-binding proteins
can cycle between a GTP-bound active state and a
w xGDP-bound inactive state 14 . RhoA, for example,
forms a complex with the GDP-dissociation inhibitor
 .Rho–GDI and remains GDP-bound in the cyto-
w xplasm 15 . The conversion from the GDP bound
inactive form to the GTP-bound active form is regu-
lated by guanine nucleotide exchange proteins such
 . w xas the GDP-dissociation stimulator Rho–GDS 16 .
RhoA in its GTP-bound form is then translocated to
w xthe membrane where it binds its target protein 17 .
Only prenylated RhoA can form complexes with
w xother proteins 13 . In the membrane, RhoA acts as a
GTPase and exchanges its bound GTP for GDP. In
the GDP-bound state, it is translocated to the cyto-
w xplasm by Rho–GDI 18 .
Most of the other members of the Ras superfamily
are presumed to go through similar cycles, although
the exact mechanisms may vary. In the presence of
lovastatin, these proteins are not able to cycle be-
cause of the absence of prenyl modification and,
therefore, an inability to form complexes with other
proteins. Because the small GTP-binding proteins are
involved in important cellular functions, this will
limit a cell’s ability to function properly. While Ras
w xis involved in cell proliferation 9 , members of the
Rho subfamily, RhoA, Rac1 and Cdc42 are associ-
ated with actin stress fiber formation, and the forma-
w xtion of lamellipodia and filopodia 19 .
Lovastatin causes cell rounding and inhibits DNA
w xsynthesis in renal mesangial cells 2 . In addition,
cells treated with lovastatin are blocked at G1 during
w xcell cycle progression 20,21 . In an effort to identify
a morphological basis for cell cycle arrest, we studied
the cells by time lapse cinematography. These studies
revealed that lovastatin prevented either cytokinesis
or cell spreading following cytokinesis. Because
RhoA plays an important role in actin stress fiber
w xassembly and cell shape in cultured cells 22 , we
proceeded to study RhoA prenylation during lovas-
tatin treatment of mesangial cells. In dividing cells
w xRhoA localizes to cleavage furrows 23 , and thus
may play a role in cytokinesis. Our results show that
lovastatin caused RhoA to accumulate in the cytosol.
The effects of lovastatin on cell function and RhoA
inactivation were prevented by the addition of far-
nesol or geranylgeraniol to the medium. Further, our
findings suggest that lovastatin-induced mesangial
cell apoptosis is caused by prolonged exposure to
conditions of reduced cellular adherence following
inhibition of post-mitotic events, a condition termed
w x‘anoikis’ 24 .
2. Experimental
2.1. Materials
Lovastatin was kindly provided by Merck, Rah-
way, NJ and was prepared as described by Kita et al.
w x25 except at pH 7.4. All-trans-farnesol and all-
 .trans-geranylgeraniol Sigma, St. Louis, MO were
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 .dissolved in ethanol 1 M and suspended in 45%
 .wrv 2-hydroxypropyl-b-cyclodextran b-CD
 .Pharmatech, Alachua, FL to a final stock concentra-
tion of 10 mM in an ultrasonic water bath for 20 min.
b-CD prevents reprecipitation of the isoprenoids upon
w xaddition to tissue culture medium 26 . The purity of
farnesol and geranylgeraniol was )95% as assessed
by gas liquid chromatography 15 m DB-23 column,
temperature programmed 105–2108C, J&W Scien-
.tific, Folsom, CA . Monoclonal anti RhoA antibody
was obtained from Santa Cruz Biotechnology, Santa
Cruz, CA.
2.2. Cell culture
Rat glomerular mesangial cells were isolated as
w xdescribed elsewhere 27 and cultured in RPMI 1640
with 20% fetal calf serum and 1% antibioticranti-
 .mycotic all from Irvine Scientific, Santa Ana, CA .
Table 1
Cell rounding observed in mesangial cells plated at 104 cells
cmy2 after 48 h of lovastatin treatment
aLovastatin concentration in mM Degree cell rounding
0 0
10 1q
20 2q
30 3q
40 3q
50 4q
a 1q, -25% of the cells rounding; 2q, 25–40% of the cells
rounding; 3q, 40–65% of the cells rounding; 4q, )65% of the
cells rounding.
2.3. Pharmacological treatments
Mesangial cells were plated at densities of 1, 2, or
3=104 cellsrcm2 in complete medium with or with-
out lovastatin. In some experiments, the lovastatin
 .Fig. 1. Mesangial cells stained with rhodamine phalloidin to demonstrate actin stress fibers. A untreated mesangial cells. Note that the
 .cells are flat and well spread and display numerous arrays of actin stress fibers. B 48 h of lovastatin treatment. Note that the cells are
 .  .round and no longer display actin stress fibers. C 48 h after lovastatin treatment in the presence of geranylgeraniol 10 mM . These cells
 .  .appear similar to untreated cells with numerous bundles of actin stress fibers. D 48 h of lovastatin treatment with farnesol 10 mM .
These cells also appear similar to untreated cells. Barss50 mm
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treated cells were also treated with farnesol or ger-
anylgeraniol in b-CD.
2.4. Western blots
Mesangial cells were grown in 100 mm tissue
culture dishes and were treated as required for pre-
determined lengths of time, at the end of which the
cells were washed two times in cold PBS, scraped in
TBS containing proteinase inhibitors and phased into
 .detergent depleted cytoplasmic and detergent-en-
 . w xriched membrane fractions using Triton X-114 28 .
Proteins were quantitated and fractionated on 12%
w xSDS–PAGE run as previously described 27 . After
electroblotting onto nitrocellulose membranes, the
blots was stained with a monoclonal antibody spe-
cific to RhoA. RhoA was detected by enhanced
chemiluminescence after incubation with a peroxi-
dase labelled secondary antibody, Pierce, Rockford,
.IL .
2.5. Examination of apoptotic cells
Apoptotic cells were identified according to the
w xfollowing criteria 29,30 : condensed and fragmented
nuclei, cell blebbing and decrease in cell size.
Fig. 2. The effect of lovastatin on the total number of mesangial
cells. The untreated cells are in a state of exponential growth.
Notice the decrease in the number of attached cells and the
increase in the number of floating cells after 48 and 72 h of
 .lovastatin 50 mM treatment. After one day of lovastatin treat-
ment there are no floating cells. This experiment represents the
average of two dishes per condition. This was repeated 4 times
with similar results. Error bars represent standard deviation from
the mean.
 .Fig. 3. The effect of lovastatin 50 mM without and with
 .  .farnesol 10 mM or geranylgeraniol 10 mM on mesangial cell
number expressed as % of control. Farnesol and geranylgeraniol
were replenished daily at the same concentrations. Notice that
farnesol was more effective than geranylgeraniol in maintaining
cell number. The number of counts represents the average of two
dishes. This experiment was repeated 4 times with similar results.
Error bars represent standard deviation from the mean.
2.5.1. Fluorescent staining
Cells were stained with the DNA binding fluo-
w xrochrome Hoechst 33258 stain 30 and nuclear mor-
phology examined under a Zeiss epifluorescence
 .photomicroscope Zeiss, Thornwood, NJ .
2.5.2. Transmission electron microscopy
Cells were fixed in 4% paraformaldehyder1%
glutaraldehyde for 30 min, scraped, and washed off
the plastic surface with 1 mg mly1 bovine serum
albumin in PBS. They were then pelleted and pro-
cessed for thick and thin sectioning.
2.6. Fluorescence microscopy
Mesangial cells were fixed with 3.7% paraformal-
dehyde in PBS for 20 min and permeabilized with
0.4% Triton X-100 in PBS for 2 min at room temper-
ature. The cells were then incubated in rhodamine–
 .phalloidin diluted 1:100 , rinsed and observed under
standard epifluorescence optics for the visualization
of actin stress fibers.
2.7. Time lapse microcinematography
Mesangial cells were plated in 25 cm2 Corning
flasks at a concentration of 2.5=105 cells per flask
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with or without 50 mM lovastatin. They were viewed
under a phase contrast microscope Nikon model
.ELWD 0.3 equipped with a time lapse video camera
 .Panasonic model AG-6030 .
2.8. Cell proliferation assay
The rate of cell proliferation was quantitated using
 .a Cell Proliferation kit Amersham, UK . Mesangial
cells were grown on glass coverslips and pulsed for 2
X  .h with 5-bromo-2 -deoxyuridine BrdU . The cells
were then treated with 50 mM lovastatin or left
untreated for different time periods, at the end of
which they were fixed in acid–ethanol. The fixed
cells were processed as per manufacturer’s instruc-
tions using an antibody to BrdU followed by a perox-
idase-conjugated secondary antibody. The number of
stained nuclei per high power field were counted and
 .Fig. 4. Phase contrast photomicrographs of the effect of cell density on lovastatin 50 mM -induced cell rounding. A, C, and E are
untreated cells plated at 1, 2, and 3=104 cells cmy2. B, D, and F are cells at the same platings as A, C, and E, respectively but treated
with lovastatin for 48 h. Greater than 65% of the cells rounded in response to lovastatin when plated at 1=104. When plated at densities
 4.which approached confluence, and, hence, exhibited contact inhibition of growth 3=10 , -25% of the cells rounded in response to
lovastatin. 200= .
( )P.M. Ghosh et al.rBiochimica et Biophysica Acta 1359 1997 13–2418
Fig. 5. Phase contrast photomicrographs of the effect of serum
 .deprivation on lovastatin 50 mM -induced cell rounding. Mesan-
gial cells were serum-deprived for 24 h and then treated with
 .lovastatin for 36 h in the absence of serum A while other cells
were serum-deprived for 24 h and then treated with lovastatin for
 .36 h in the presence of serum B . Bars50 mm.
were expressed as the percentage of stained vs. un-
stained cells.
3. Results
3.1. Effect of lo˝astatin on mesangial cell morphol-
ogy
Lovastatin induced a dose-dependent effect on
 .mesangial cell morphology Table 1 . Greater than
65% of the cells plated in the presence of 50 or 100
Fig. 6. Images from time lapse microcinematography of untreated
mesangial cells. Cell division was first apparent 18 h after
plating. The arrow depicts a cell which is undergoing division.
Approximately 45 min elapse from the time cytokinesis is first
 .evident top image, cell has one edge lifted off surface until the
 .two daughter cells have respread over the surface bottom panel .
mM lovastatin changed shape from flat cells with
 .actin stress fibers Fig. 1A to round cells without
 .actin stress fibers Fig. 1B . By 48 h, ca. 50% of the
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 .cells were detached from the substratum Fig. 2 ; for
the most part, the remaining cells still attached to the
 .substratum were rounded Fig. 1B . By 72 h, ca. 90%
Fig. 8. Morphological characteristics of mesangial cells cultured
in 50 mM lovastatin for 48 h. Cells were stained with the DNA
binding fluorochrome Hoechst 33258 and examined under a
epifluorescence photomicroscope with a water immersible lens.
 .All the stained cells floated in the medium arrows . Notice the
nuclear condensation, fragmented cell nucleus and decreased cell
size, features of apoptotic cells. The attached cells did not stain
with Hoechst. Bars50 mm.
 .of the cells were floating in the medium Fig. 2 .
Lovastatin-induced cell rounding was reversible by
replacement with lovastatin-free medium; however,
floating cells could not be stimulated to readhere in
the absence of lovastatin. Inclusion of geranylgeran-
iol or farnesol dissolved in b-CD in the incubation
medium together with lovastatin largely prevented
cell rounding and loss of actin stress fibers Fig. 1C
.and D as well as cell detachment and inhibition of
 .cell proliferation Fig. 3 . b-CD alone had no effect
on mesangial cell morphology or adhesion.
3.2. Dependence of cell rounding on cell growth
Mesangial cells plated at low plating densities
were affected most by lovastatin with )65% of the
 .cells rounded Fig. 4B . However, plating cells at
densities which resulted in confluent monolayers,
where proliferation was inhibited by cell–cell con-
Fig. 7. Images from time lapse microcinematography of cells
plated in the presence of 50 mM lovastatin. The top image shows
two cells beginning to undergo mitosis. As is evident from the
 .remaining images, one cell, depicted with an arrowhead , under-
goes cytokinesis but the daughter cells do not spread over the
 .surface even after 2.5 h; the other cell, depicted with an arrow
fails to undergo cytokinesis and remains round. Also, note the
rounded cell along the left hand margin which had divided at
some time previously but failed to spread.
( )P.M. Ghosh et al.rBiochimica et Biophysica Acta 1359 1997 13–2420
( )P.M. Ghosh et al.rBiochimica et Biophysica Acta 1359 1997 13–24 21
Fig. 10. Western blot analysis of the effect of lovastatin on RhoA
localization. Mesangial cells were incubated with lovastatin 50
.mM for 48 h, harvested and extracted with Triton X-114 into
 .  .cytosolic c and membrane m cellular fractions. PAGE was
performed and proteins electroblotted and stained with an anti-
 .body to RhoA. Untreated mesangial cells A displayed im-
munoreactive RhoA in the membrane fraction. Treatment with
 .lovastatin alone B caused RhoA to accumulate in the cytosolic
 .fraction. Incubation in geranylgeraniol with lovastatin C re-
sulted in a complete return of RhoA to the membrane cellular
 .fraction while incubation in farnesol with lovastatin D resulted
in only partial restoration. The arrow represents a 21 kDa protein
marker.
tact, largely prevented cell rounding in the presence
of the same concentration of lovastatin Fig. 4D and
.F . Likewise, prevention of cell growth by serum
deprivation for 48 h inhibited cell rounding induced
by lovastatin, whereas the same cells exhibited cell
rounding in the presence of lovastatin when serum
was added back to the culture medium and cell
 .division was stimulated Fig. 5 .
3.3. Sequence of e˝ents leading to G1 arrest in
lo˝astatin
Mesangial cells were observed under time-lapse
cinematography for a period of 48 h with and without
lovastatin. Without lovastatin, mesangial cells were
quiescent for a period of ca. 18 h after plating before
evidence of cytokinesis was first observed. Immedi-
ately prior to cell division, cells detached from one
edge and rounded up. Cell division followed within
45 min with the daughter cells moving apart from
one another, and subsequently spreading out again
 .Fig. 6 .
Plating cells into medium containing 50 mM lovas-
Fig. 11. Mesangial cells were pulsed with BrdU for 2 h and
 .exposed to lovastatin 50 mM for 2, 4, and 7 h. Cells were fixed
and stained with an antibody to BrdU followed by a peroxidase-
conjugated secondary antibody. Cell proliferation index was de-
termined by calculating the percentage of cells exhibiting nuclear
staining for BrdU.
tatin did not affect plating efficiency or initial cell
spreading. Lovastatin’s effect on the cells was not
obvious until the cells were in mitosis. At this stage,
the cells were observed to behave in one of the
 .following manners in the presence of lovastatin: 1
After completion of cell division, the cells remained
rounded and attached to the substratum; they did not
 .respread, or 2 cytokinesis was inhibited and the
cells remained in a rounded morphology. Both exam-
ples are shown in Fig. 7. Review of the entire video
tape revealed that ca. 80% of the cells underwent cell
division but did not respread while the remaining
cells did not undergo cytokinesis.
3.4. Isoprenoid induced reco˝ery of mesangial cells
Time lapse studies revealed that the addition of
geranylgeraniol or farnesol to the rounded cells within
48 h of lovastatin treatment, caused the cells to
respread andror undergo cytokinesis similar to the
untreated cells. Cells which were treated with lovas-
tatin for longer periods of time could not be induced
to respread. Similar results were obtained with ger-
 .  .Fig. 9. Ultrastructural appearance of mesangial cells either untreated A or treated with 50 mM lovastatin for 48 h B, C . The untreated
cells were attached to the substratum. Notice the characteristic spindle shape of mesangial cells with elliptical-shaped nucleus. B and C
 .represent cells treated with lovastatin which were floating in the medium. Notice in B the nuclear chromatin condensation arrowheads
 .and in C the fragmented nucleus arrowheads , both characteristics of apoptotic cells. The attached cells incubated with lovastatin were
 .round but displayed no evidence of apoptosis not shown . Barss2 mm.
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anylgeranyl pyrophosphate and farnesyl pyrophos-
 .phate data not shown .
3.5. Induction of apoptosis
Mesangial cells were plated at a density of 2=104
cells cmy2 and treated with 50 mM lovastatin for 24,
48 and 72 h. Floating and attached cells were stained
with Hoechst stain and nuclear morphology exam-
ined. All of the floating cells observed after 48 and
72 h of lovastatin treatment stained with Hoechst
33258 see Fig. 8 for appearance of cells after 48 h of
.lovastatin treatment . This staining revealed diagnos-
tic features of apoptosis; namely, nuclear condensa-
tion and fragmentation, and decrease in cell size Fig.
.8 . Cell blebbing was also observed. None of the
rounded, attached cells stained with Hoechst 33258.
In other experiments, cells were plated at 1.3=104
cells cmy2, and treated with 50 mM lovastatin for 48
h. Floating and attached cells were examined by
electron microscopy. Normal mesangial cells were
flat spindle-shaped cells with elliptical shaped nuclei
 .Fig. 9A . After lovastatin treatment the attached
cells were rounded with intact nuclei, and no evi-
 .dence of apoptosis was apparent data not shown .
However, all floating cells were apoptotic, character-
 .ized by condensed nuclear chromatin Fig. 9B and
 .fragmented nuclei Fig. 9C .
3.6. Cellular localization of RhoA
To detect the cellular localization of RhoA,
glomerular mesangial cells were treated with or with-
out lovastatin in the presence or absence of farnesol
or geranylgeraniol, and extracted with Triton X-114.
After separation into cytosolic and membrane frac-
tions, proteins were fractionated by SDS–PAGE,
electroblotted onto nitrocellulose and stained with an
antibody to RhoA. As shown in Fig. 10, in untreated
mesangial cells, the immunoreactive RhoA was found
 .in the membrane fraction lane A . However, lovas-m
tatin treatment for 48 h caused RhoA to accumulate
 .in the cytosolic fraction lane B , suggestive ofC
 .inactivation of RhoA 13 . Mesangial cells treated
with lovastatin in the presence of geranylgeraniol
displayed a similar location of RhoA as untreated
 .cells, that is, in the membrane fraction lane C .m
Farnesol treatment resulted in partial restoration of
 .RhoA to the membrane fraction lane D .m
3.7. Measure of cell proliferation
Mesangial cells were pulsed for 2 h with BrdU
after exposure to lovastatin for 2, 4 or 7 h. As shown
in Fig. 11, nuclear staining for BrdU did not change
in the presence of lovastatin, confirming our observa-
tions that cell growth was necessary for lovastatin to
affect cell morphology. Lovastatin decreased mesan-
gial cell proliferation as evidenced by decreased nu-
clear staining for BrdU subsequent to cell rounding
 .data not shown .
4. Discussion
The HMG–CoA reductase inhibitor lovastatin has
w xbeen reported to inhibit DNA synthesis 2,31,32 , and
w xcell proliferation 2,33,34 and to cause apoptosis in
w xcultured cells 3,32 . It has been shown that these
effects of lovastatin could be reversed by the addition
w x w xof mevalonic acid 21 or by farnesol 2 or geranyl-
w xgeraniol 37,38 . It is well established that this is due
to prevention of isoprenylation of small GTP-binding
w xproteins that are involved in these processes 1,2 .
Although lovastatin is known to block cell cycle
w xprogression at G1 20,21 , the morphological basis
for this is unknown. Our time lapse studies demon-
strate that lovastatin blocks cell cycle progression at
early G1 by preventing cell spreading andror cytoki-
nesis. Lovastatin is thus able to affect proliferating
cells much more readily than non-proliferating cells.
Time lapse cinematography showed that the mi-
totic process in glomerular mesangial cells normally
takes less than 1 h to complete; however, in the
presence of lovastatin, some cells that had completed
mitosis did not respread while other cells failed to
undergo cytokinesis. This is contrary to the common
w xbelief that lovastatin inhibits DNA synthesis 2,32 .
Also, our data shows that in mesangial cells lovas-
tatin does not cause cell-rounding; rather, lovastatin
prevents cells, which had already rounded up to
undergo mitosis, from spreading back again. The fact
that lovastatin-induced cell rounding is dependent on
cell proliferation is further supported by the observa-
tion that BrdU uptake was not prevented by lovas-
tatin in actively dividing cells, and that inhibition of
cell growth, either by serum starvation or by contact
inhibition, prevented this effect. Most studies report-
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ing inhibition of DNA synthesis in the presence of
w xlovastatin 2,32 measure DNA synthesis at a much
later time, usually 42 h after the addition of lovas-
tatin, when cell rounding has already occurred.
The cell rounding and loss of actin stress fibers
was followed by cell detachment and apoptosis. Ad-
herent cells maintained in suspension for long periods
undergo apoptosis due to a failure to produce p125FAK
w x24,35 . This subtype of apoptosis was termed ‘anoi-
kis’ or loneliness. Our data demonstrated that lovas-
tatin-treated cells underwent ‘anoikis’ due to a loss of
cell adhesion. This was supported by the observation
that lovastatin-treated round cells still attached to the
substratum did not undergo apoptosis, while the de-
tached and floating cells did. The effects of lovastatin
could be prevented by the addition of farnesol or
geranylgeraniol to the medium specifying the action
of lovastatin to its inhibition of isoprenoid synthesis.
 .We chose to study RhoA because a RhoA has
been implicated in the formation of actin stress fibers
w xand focal adhesion 22 and would therefore be in-
 .volved in cell spreading, b RhoA localizes to cleav-
w xage furrows 23 and therefore may be involved in
 . FAKcytokinesis and c RhoA acts upstream of p125
w x36 and is probably involved with the prevention of
anoikis. Prevention of geranylgeranylation would in-
hibit targeting of RhoA to its active site on the
membrane as well as its interaction with other pro-
teins and therefore its function as a GTPase. Indeed,
mesangial cells treated with lovastatin accumulate
RhoA in the cytosolic fraction, indicative of inactive
RhoA. Although both farnesol and geranygeraniol are
capable of inhibiting lovastatin’s action on cell
rounding and stress fiber disassembly, only geranyl-
geraniol returned RhoA distribution to the membrane
fraction completely. This implies that other small
GTP-binding proteins in addition to RhoA participate
in cell spreading and actin stress fiber assembly,
especially ones that are farnesylated. One candidate is
RhoB which can be either geranylgeranylated or far-
nesylated, and whose function is not clearly defined
w x10 .
Addition of farnesol or geranylgeraniol also pre-
vented inhibition of cell proliferation and anoikis
induced by lovastatin treatment, but farnesol ap-
peared to be more effective than geranylgeraniol Fig.
.3 . These results in mesangial cells are contrary to
those found in other cell lines in which farnesol was
ineffective in preventing the effects of lovastatin
w x37,38 . Our results on mesangial cells imply the
involvement of both farnesylated and geranylgerany-
lated proteins in cell proliferation.
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